inositol has been researched along with miglitol in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Mooradian, AD; Thurman, JE | 1 |
| Scheen, AJ | 1 |
| Akkermans, RP; Lucassen, PL; Rutten, GE; Van de Laar, FA; Van de Lisdonk, EH; Van Weel, C | 1 |
| Kasuga, M; Sakaguchi, K | 1 |
| Daida, H; Fukao, K; Fukushima, Y; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miida, T; Miyazaki, T; Ohmura, H; Ohsaka, H; Shimada, K; Sumiyoshi, K | 1 |
| An, N; Dai, XM; Li, HY; Wu, JM; Zhang, QM | 1 |
| Fujita, H; Hosoba, M; Morii, T; Narita, T; Sato, T; Tsukiyama, K; Yamada, Y; Yamashita, R; Yokoyama, H | 1 |
| Schnell, O; Standl, E | 1 |
| Fujii, M; Ichikawa, M; Imagawa, M; Inaba, S; Kimura, T; Konoshita, T; Miyamori, I; Sato, S; Suzuki, J; Takahashi, S; Zenimaru, Y | 1 |
| Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K | 1 |
| Fuchigami, M; Goda, T; Hariya, N; Inoue, S; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Babu, RJ; Dash, RP; Srinivas, NR | 1 |
| Jedrzejczak, RP; Joachimiak, A; Tan, K; Tesar, C; Wilton, R | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Alssema, M; Blaak, EE; Dekker, JM; Denise Robertson, M; Dussort, P; Egli, L; Ruijgrok, C; Vinoy, S | 1 |
| Kaur, N; Kaur, P; Kumar, V; Nayak, SK; Sahu, SK; Wadhwa, P | 1 |
8 review(s) available for inositol and miglitol
| Article | Year |
|---|---|
Drug therapy of postprandial hyperglycaemia.
Topics: 1-Deoxynojirimycin; Acarbose; Amyloid; Carbamates; Diabetes Mellitus; Enzyme Inhibitors; Glucosamine; Glyburide; Humans; Hyperglycemia; Hypoglycemic Agents; Imino Pyranoses; Inositol; Insulin; Insulin Lispro; Islet Amyloid Polypeptide; Piperidines; Postprandial Period; Trisaccharides | 1999 |
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2003 |
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Inositol; Randomized Controlled Trials as Topic | 2005 |
[Adverse effects of alpha-glucosidase inhibitors].
Topics: 1-Deoxynojirimycin; Acarbose; Digestive System Diseases; Drug Interactions; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperammonemia; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Inositol | 2007 |
Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol | 2012 |
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Metformin; Prediabetic State | 2019 |
Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus; Glucose; Glycoside Hydrolase Inhibitors; Humans; Inositol; Insulin; Postprandial Period | 2021 |
Alpha-amylase as molecular target for treatment of diabetes mellitus: A comprehensive review.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Amylases; Benzofurans; Blood Glucose; Diabetes Mellitus; Drug Discovery; Flavonoids; Glycoside Hydrolase Inhibitors; Humans; Hydrazones; Hypoglycemic Agents; Indoles; Inositol; Oxadiazoles; Structure-Activity Relationship | 2021 |
6 trial(s) available for inositol and miglitol
| Article | Year |
|---|---|
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic p
Topics: 1-Deoxynojirimycin; Aged; Coronary Artery Disease; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Glucose; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Inositol; Lipid Metabolism; Male; Middle Aged; Treatment Outcome | 2010 |
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Inositol; Male; Middle Aged; Obesity; Postprandial Period | 2012 |
Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Topics: 1-Deoxynojirimycin; Apolipoprotein A-I; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Lispro; Lipids; Lipoproteins, HDL; Male; Middle Aged; Postprandial Period; Treatment Outcome; Triglycerides | 2012 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Asian People; Blood Glucose; Cardiovascular Diseases; Chemokine CCL2; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Prospective Studies; Risk Factors; Time Factors | 2014 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
4 other study(ies) available for inositol and miglitol
| Article | Year |
|---|---|
Development and validation of HPLC-UV-MS method for the control of four anti-diabetic drugs in suspected counterfeit products.
Topics: 1-Deoxynojirimycin; Acarbose; alpha-Glucosidases; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet | 2010 |
Intestinal alpha-glucosidase inhibitors: abdominal gas cysts.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Aged, 80 and over; alpha-Glucosidases; Enzyme Inhibitors; Female; Gases; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Intestinal Mucosa; Male; Middle Aged; Pneumatosis Cystoides Intestinalis; Predictive Value of Tests; Risk Assessment; Risk Factors | 2012 |
Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Inositol | 2018 |
Interaction of antidiabetic α-glucosidase inhibitors and gut bacteria α-glucosidase.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Bacterial Proteins; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Models, Molecular; Protein Binding; Ruminococcus | 2018 |